Skip to main content
BrainCited

Omega-3 Fatty Acids (DHA/EPA) per Depression-Related Cognitive Dysfunction

B Evidenze Almeno un trial randomizzato lo supporta, con risultati per lo più coerenti.

Research suggests fish oil supplements may help support memory function and are also associated with improved outcomes in people experiencing depression-related cognitive symptoms.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Domega\u002D3\u002Ddha\u002Depa\u0026condition\u003Ddepression\u002Dcognitive'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

In sintesi

Research suggests fish oil supplements may help support memory function and are also associated with improved outcomes in people experiencing depression-related cognitive symptoms.

Key Study Findings

Review
The Clinical Implications of Ashwagandha (Withania somnifera L.) with a Special Reference to Side Effects-A …
Dose: None vs: None Outcome: None Effetto: None None

Popolazione: narrative review of ashwagandha clinical trials and basic research (1994-present)

preclinical animal/in vitro study
Ashwagandha (Withania somnifera (L.) dunal) root extract containing withanolide a alleviates depression-like behavior in mice …
Dose: 60 and 100 mg/kg (mice); 100 and 200 µg/mL (HT-22 cells); withanolide A 1.56 and 3.12 µg/mL vs: Placebo Effetto: None None
Review
[Pharmacotherapies for insomnia].
Dose: Z-drugs, melatonin, orexin antagonists vs: None Outcome: Insomnia treatment efficacy and safety Effetto: None None

Popolazione: Adults with chronic insomnia

In Vitro
Oxytocin and Vasopressin Gene Expression in the Brain as Potential Biomarkers for Cannabidiol Therapeutic Efficacy.
Dose: Cannabidiol (CBD) vs: Vehicle control Outcome: Oxytocin and vasopressin gene expression Effetto: None None

Popolazione: EAE mouse model (multiple sclerosis)

Meta-Analysis
Effects of vitamins and polyunsaturated fatty acids on cognitive function in older adults with mild …
Dose: None vs: Control Outcome: Cognitive function Effetto: SMD = 0.58, 95% CI = [0.20, 0.96] P = 0.003

Popolazione: Patients with mild cognitive impairment

Controlled Clinical Trial
Prolonging effects of Valeriana fauriei root extract on pentobarbital-induced sleep in caffeine-induced insomnia model mice …
Dose: 5 g/kg or 10 g/kg (as VF) vs: Caffeine-induced insomnia without VF Outcome: Sleep latency and duration (pentobarbital-induced) Effetto: None None

Popolazione: Caffeine-induced insomnia model mice

Key Statistics

15

Studi

2500

Partecipanti

Positive

B

Grado

Referenced Papers

La Revue du … 2024
Nature reviews. Disease … 2021 163 citazioni
The Senior care … 2021 2 citazioni
Journal of ethnopharmacology 2020 85 citazioni
Current neurology and … 2019 11 citazioni
Sleep medicine 2017 95 citazioni
Current treatment options … 2017 56 citazioni
Clinical therapeutics 2016 328 citazioni
The Cochrane database … 2003 263 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
1,000-2,000 mg combined DHA/EPA per day
cognitivesupport:
1,000-1,700 mg/day (optimal dose-response curve)

Limite massimo: 3,000 mg/day combined DHA/EPA (FDA GRAS)

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
None -- Positive --
60 and 100 mg/kg (mice); 100 and 200 µg/mL (HT-22 cells); withanolide A 1.56 and 3.12 µg/mL -- Positive --
Z-drugs, melatonin, orexin antagonists -- Positive --
Cannabidiol (CBD) -- Positive --
None -- Positive --
5 g/kg or 10 g/kg (as VF) -- Positive --
10, 25, or 50 mg/kg body weight ashwagandha extract (AE, 35% withanolide glycosides, Shoden) -- Positive --
None -- Mixed --

Momento migliore per l'assunzione: With meals containing fat for better absorption

Safety & Side Effects

Effetti collaterali segnalati

  • Fishy aftertaste or burping
  • Mild gastrointestinal discomfort
  • Potential increased bleeding time at very high doses
  • May lower blood pressure slightly

Interazioni note

  • Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
  • Blood pressure medications (additive hypotensive effect)
  • Orlistat (may reduce omega-3 absorption)

Livello di assunzione massimo tollerabile: 3,000 mg/day combined DHA/EPA (FDA GRAS)

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Omega-3 Fatty Acids (DHA/EPA) help with Depression-Related Cognitive Dysfunction?
Based on 15 studies with 2,500 participants, there is moderate evidence from clinical studies that Omega-3 Fatty Acids (DHA/EPA) may support Depression-Related Cognitive Dysfunction management. Our evidence grade is B (Good Evidence).
How much Omega-3 Fatty Acids (DHA/EPA) should I take for Depression-Related Cognitive Dysfunction?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined DHA/EPA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (DHA/EPA)?
Reported side effects may include Fishy aftertaste or burping, Mild gastrointestinal discomfort, Potential increased bleeding time at very high doses, May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (DHA/EPA) and Depression-Related Cognitive Dysfunction?
We rate the evidence as Grade B (Good Evidence). This rating is based on 15 peer-reviewed studies with 2,500 total participants. The overall direction of effect is positive.

Altri ingredienti per Depression-Related Cognitive Dysfunction

References

  1. [1] Kaj Winther. Nutrients. 2026. The Clinical Implications of Ashwagandha (Withania somnifera L.) with a Special Reference to Side Effects-A Review. doi:10.3390/nu18050871 PubMed
  2. [2] Hyeongyeong Kim et al.. J Ethnopharmacol. 2025. Ashwagandha (Withania somnifera (L.) dunal) root extract containing withanolide a alleviates depression-like behavior in mice by enhancing the brain-derived neurotrophic … doi:10.1016/j.jep.2024.119224 PubMed
  3. [3] Jing Chang et al.. Eur J Nutr. 2024. Effects of vitamins and polyunsaturated fatty acids on cognitive function in older adults with mild cognitive impairment: a meta-analysis of … doi:10.1007/s00394-024-03324-y PubMed
  4. [4] Christa M Frodella et al.. Biomedicines. 2024. Oxytocin and Vasopressin Gene Expression in the Brain as Potential Biomarkers for Cannabidiol Therapeutic Efficacy. doi:10.3390/biomedicines12061273 PubMed
  5. [5] Marie-Françoise Vecchierini et al.. Rev Prat. 2024. [Pharmacotherapies for insomnia]. PubMed
  6. [6] Sindgi Vasudeva Murthy et al.. Prev Nutr Food Sci. 2022. Hydroalcoholic Extract of Ashwagandha Improves Sleep by Modulating GABA/Histamine Receptors and EEG Slow-Wave Pattern in In Vitro - In Vivo … doi:10.3746/pnf.2022.27.1.108 PubMed
  7. [7] Vincent Beliveau et al.. Neuroimage Clin. 2022. Revisiting brain iron deficiency in restless legs syndrome using magnetic resonance imaging. doi:10.1016/j.nicl.2022.103024 PubMed
  8. [8] Misato Ota et al.. J Ethnopharmacol. 2022. Prolonging effects of Valeriana fauriei root extract on pentobarbital-induced sleep in caffeine-induced insomnia model mice and the pharmacokinetics of its … doi:10.1016/j.jep.2022.115625 PubMed
  9. [9] Yulin Sun et al.. BMJ Open. 2022. Melatonin supplementation for the treatment of infantile spasms: protocol for a randomised placebo-controlled triple-blind trial. doi:10.1136/bmjopen-2021-057970 PubMed
  10. [10] Mauro Manconi et al.. Nat Rev Dis Primers. 2021. Restless legs syndrome. doi:10.1038/s41572-021-00311-z PubMed
  11. [11] Heba M A Khalil et al.. J Ethnopharmacol. 2021. Ashwagandha (Withania somnifera) root extract attenuates hepatic and cognitive deficits in thioacetamide-induced rat model of hepatic encephalopathy via induction of … doi:10.1016/j.jep.2021.114141 PubMed
  12. [12] Rodiya Manor et al.. J Ethnopharmacol. 2021. Characterization of pharmaco-EEG fingerprint and sleep-wake profiles of Lavandula angustifolia Mill. essential oil inhalation and diazepam administration in rats. doi:10.1016/j.jep.2021.114193 PubMed
  13. [13] Brittany R Block et al.. Sr Care Pharm. 2021. Online Promotion of "Brain Health" Supplements. doi:10.4140/TCP.n.2021.489 PubMed
  14. [14] Isabella C Arellanes et al.. EBioMedicine. 2020. Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial. doi:10.1016/j.ebiom.2020.102883 PubMed
  15. [15] Nawab John Dar et al.. J Ethnopharmacol. 2020. Neurodegenerative diseases and Withania somnifera (L.): An update. doi:10.1016/j.jep.2020.112769 PubMed
  16. [16] Jennifer L Martin et al.. J Clin Sleep Med. 2020. The Veterans Administration and Department of Defense clinical practice guidelines for the diagnosis and management of sleep disorders: what does … doi:10.5664/jcsm.8486 PubMed
  17. [17] Jerome Sarris et al.. J Psychiatr Res. 2019. L-theanine in the adjunctive treatment of generalized anxiety disorder: A double-blind, randomised, placebo-controlled trial. doi:10.1016/j.jpsychires.2018.12.014 PubMed
  18. [18] Valérie Cochen De Cock et al.. Curr Neurol Neurosci Rep. 2019. Sleep Disorders in Wilson's Disease. doi:10.1007/s11910-019-1001-4 PubMed
  19. [19] Giovanni Rizzo et al.. Sleep Med. 2017. Brain imaging and networks in restless legs syndrome. doi:10.1016/j.sleep.2016.07.018 PubMed
  20. [20] G Iolascon et al.. J Nutr Health Aging. 2017. Are Dietary Supplements and Nutraceuticals Effective for Musculoskeletal Health and Cognitive Function? A Scoping Review. doi:10.1007/s12603-016-0823-x PubMed
  21. [21] Amy W Amara et al.. Curr Treat Options Neurol. 2017. Treatment of Sleep Dysfunction in Parkinson's Disease. doi:10.1007/s11940-017-0461-6 PubMed
  22. [22] Jennifer L Schroeck et al.. Clin Ther. 2016. Review of Safety and Efficacy of Sleep Medicines in Older Adults. doi:10.1016/j.clinthera.2016.09.010 PubMed
  23. [23] Yoan Cherasse et al.. Mol Nutr Food Res. 2015. Zinc-containing yeast extract promotes nonrapid eye movement sleep in mice. doi:10.1002/mnfr.201500082 PubMed
  24. [24] Anna K Morin et al.. Pharmacotherapy. 2007. Therapeutic options for sleep-maintenance and sleep-onset insomnia. doi:10.1592/phco.27.1.89 PubMed
  25. [25] Chun-Su Yuan et al.. Anesth Analg. 2004. The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity. doi:10.1213/01.ANE.0000096189.70405.A5 PubMed
  26. [26] M Malouf et al.. Cochrane Database Syst Rev. 2003. Folic acid with or without vitamin B12 for cognition and dementia. doi:10.1002/14651858.CD004514 PubMed
  27. [27] B Enkvetchakul et al.. Poult Sci. 1995. Influence of diethyl maleate and cysteine on tissue glutathione and growth in broiler chickens. doi:10.3382/ps.0740864 PubMed

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.